Yao Peng, Deng Yi-Yong, Hong Tao, Wang Zhi-Bin, Ma Jia-Ming, Zhu Yong-Qiang, Li Hong-Xi, Ding Yuan-Yuan, Pan Shi-Nong
aDepartment of Pain Management, Shenjing Hospital of China Medical University, Shenyang bDepartment of Pain Management, Siping Hospital of China Medical University (Siping Central Hospital of Jilin Province), Siping cDepartment of Radiology, Shenjing Hospital of China Medical University, Shenyang, China.
Medicine (Baltimore). 2016 Jun;95(26):e4019. doi: 10.1097/MD.0000000000004019.
Radiofrequency thermocoagulation (RFT) is widely used to treat trigeminal neuralgia (TN); however, the optimal temperature at which RFT is most efficacious remains under much debate. Thus, the aim of the present study was to determine the lowest temperature at which morbidity could be minimized and patient outcomes maximized.A multivariate analysis was used to study 1354 patients who underwent computed tomography (CT)-guided RFT for V2/V3 idiopathic trigeminal neuralgia (ITN) during from June 2006 to May 2015. RFT was carried out at 62, 65, and 68°C, while keeping all other RF parameters the same. This was a prospective cohort study, in which we assessed intra- and postoperative complications, pain relief, and long-term health-related quality of life (HRQoL).The intraoperative and in-hospital complications of patients were mainly facial hematoma, mouth and external auditory meatus penetration, nausea, vomiting, dizziness, and headache, which were all treated symptomatically. In long-term follow-up, patients with pain relief (defined as no pain and no required drug intervention) at 62, 65, and 68°C accounted for 94.2%, 98.3%, and 98.8% (at discharge); 83.8%, 90.1%, and 91.4% (at 1 year); 66.7%, 80.5%, and 88.2% (at 3 years); 59.0%, 64.3%, and 77.2% (at 5 years); 48.7%, 57.8%, and 72.3% (at 7 years); 40.6%, 53.7%, and 60.3% (at 9 years), respectively. The number of patients with facial numbness, masticatory atonia, or corneal hypoesthesia was increased with the elevation of temperature, but these complications were all mild. No blindness, deafness, intracranial hemorrhage, or death as a result of the surgical intervention occurred in any patients. SF-36 scores showed highest HRQoL in the group treated at 68°C, followed by the 65 and 62°C groups, respectively.Our results demonstrate that 68°C is a good choice for RFT of V2/V3 ITN. The alternative option is 65 or 62°C for RFT to minimize the occurrence of complications including facial numbness, yet which often yields a higher recurrence rate.
射频热凝术(RFT)被广泛用于治疗三叉神经痛(TN);然而,RFT最有效的最佳温度仍存在诸多争议。因此,本研究的目的是确定能将发病率降至最低且使患者预后最大化的最低温度。
采用多变量分析研究了2006年6月至2015年5月期间接受计算机断层扫描(CT)引导下RFT治疗V2/V3特发性三叉神经痛(ITN)的1354例患者。RFT在62、65和68°C下进行,同时保持所有其他射频参数相同。这是一项前瞻性队列研究,我们评估了术中及术后并发症、疼痛缓解情况以及长期健康相关生活质量(HRQoL)。
患者的术中及院内并发症主要为面部血肿、口腔及外耳道穿透、恶心、呕吐、头晕和头痛,均进行了对症治疗。在长期随访中,62、65和68°C下疼痛缓解(定义为无疼痛且无需药物干预)的患者比例分别为94.2%、98.3%和98.8%(出院时);83.8%、90.1%和91.4%(1年时);66.7%、80.5%和88.2%(3年时);59.0%、64.3%和77.2%(5年时);48.7%、57.8%和72.3%(7年时);40.6%、53.7%和60.3%(9年时)。面部麻木、咀嚼肌麻痹或角膜感觉减退的患者数量随温度升高而增加,但这些并发症均较轻微。所有患者均未因手术干预出现失明、耳聋、颅内出血或死亡。SF - 36评分显示,68°C治疗组的HRQoL最高,其次分别是65和62°C组。
我们的结果表明,68°C是V2/V3 ITN的RFT的良好选择。另一种选择是65或62°C进行RFT,以尽量减少包括面部麻木在内的并发症的发生,但这通常会导致较高的复发率。